The enhanced production of endothelial cell-derived vasoactive mediators an
d the activation of mast cells (MCs) have been implicated in the pathogenes
is of mucosal damage during ischemia and reperfusion injuries. The first ob
jective of our study was to define the in vivo relation between endothelin-
l (ET-1) and the MC system. Secondly, we determined whether pretreatment wi
th ET receptor antagonists would attenuate MC responses to exogenous ET-1.
In the first series of experiments, increasing doses of ET-1 (0.1, 1 and 3
nmol/kg i.v.) were administered to anesthetized rats. In the second series,
the animals were pretreated with equimolar doses of the ET-A receptor anta
gonist BQ-610 or ETR-P1/fl peptide, and the ET-B receptor antagonist IRL-10
38. Intestinal perfusion changes and macrohemodynamics were recorded, and t
he proportion of degranulated MCs was determined in ileal biopsies. The ave
rage mucosal thickness was recorded with an image analysis system. ET-I ind
uced dose-dependent alterations in the hemodynamic and morphological parame
ters and caused pronounced mucosal injury, with a significant reduction in
villus height. The ratio of degranulated MCs was similar in all ET-treated
groups (77%, 82% and 86%) to that observed in animals subjected to 15-min i
schemia and 60-min reperfusion (85% degranulation). Pretreatment with BQ-61
0 and ETR-P1/fl peptide attenuated the ET-1 induced alterations in the hemo
dynamic parameters and decreased structural injury to the mucosa. ET-induce
d MC degranulation was significantly inhibited by the ET-A receptor antagon
ists, but not by IRL-1038. These results indicate that elevated levels of c
irculating ET-1 might induce intestinal mucosal tissue injury and MC degran
ulation via activation of ET-A receptors, and raise the possibility that ET
-A receptor antagonist administration could exert a potentially beneficial
effect through a mechanism other than the blockade of vasoconstriction in p
athologies associated with an increased ET-1 release. (C) 2000 Elsevier Sci
ence Inc. All rights reserved.